3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
4
Completed
4
Active not recruiting
2
Unknown
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Conditions
Breast Neoplasms
116
Carcinoma, Non-Small-Cell Lung
68
Multiple Myeloma
56
Prostatic Neoplasms
55
Lymphoma
40
Neoplasm Metastasis
38
Leukemia, Lymphocytic, Chronic, B-Cell
35
Melanoma
32
Leukemia, Myeloid, Acute
32
Neoplasms
31
Ovarian Neoplasms
30
Lymphoma, Non-Hodgkin
27
Lung Neoplasms
26
Hematologic Neoplasms
25
Triple Negative Breast Neoplasms
24
Glioblastoma
22
Myelodysplastic Syndromes
20
Fallopian Tube Neoplasms
20
Precursor Cell Lymphoblastic Leukemia-Lymphoma
19
Hodgkin Disease
19
Sarcoma
18
Carcinoma, Renal Cell
18
Squamous Cell Carcinoma of Head and Neck
16
Small Cell Lung Carcinoma
16
Glioma
16
Urinary Bladder Neoplasms
15
Colorectal Neoplasms
15
Lymphoma, Mantle-Cell
14
Leukemia
14
Head and Neck Neoplasms
14
Interventions
rucaparib
1
olaparib
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Has results
×
Pathologic Complete Response
×
Clear all
NCT01844986
2025-12-10
SOLO-1
AstraZeneca
Phase 3
Active not recruiting
450 enrolled
18 charts
1 FDA
NCT03522246
2025-06-24
ATHENA
pharmaand GmbH
Phase 3
Active not recruiting
1,097 enrolled
26 charts